TY - JOUR
T1 - Update on the management of atrial fibrillation
T2 - Anticoagulation and medical therapy
AU - Lim, Shueh Hao
AU - Calkins, Hugh
AU - Sinha, Sunil K.
PY - 2011/10
Y1 - 2011/10
N2 - 2010 saw the introduction of dabigatran (Pradaxa; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT), following US Food and Drug Administration approval, into daily clinical practice in the United States as an alternative to Coumadin (Bristol-Myers-Squibb, New York, NY) therapy. Dronedarone (Multaq; Sanofi-Aventis, Bridgewater, NJ), originally approved for use in the United States in 2009, has seen further widespread deployment in contemporary clinical practice. Intravenous vernakalant (Cardiome Pharm, Vancouver, B.C., Canada; Merck &Co., Whitehouse Station, NJ) is being considered for approval in the United States and may serve as an alternative to current agents for safe and efficacious acute conversion from atrial fibrillation. We focus primarily on new information concerning these and other antiarrhythmic drug and anticoagulation therapies. We provide brief updates of recently published articles along with our perspective on how they will likely alter clinical practice now and in the future.
AB - 2010 saw the introduction of dabigatran (Pradaxa; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT), following US Food and Drug Administration approval, into daily clinical practice in the United States as an alternative to Coumadin (Bristol-Myers-Squibb, New York, NY) therapy. Dronedarone (Multaq; Sanofi-Aventis, Bridgewater, NJ), originally approved for use in the United States in 2009, has seen further widespread deployment in contemporary clinical practice. Intravenous vernakalant (Cardiome Pharm, Vancouver, B.C., Canada; Merck &Co., Whitehouse Station, NJ) is being considered for approval in the United States and may serve as an alternative to current agents for safe and efficacious acute conversion from atrial fibrillation. We focus primarily on new information concerning these and other antiarrhythmic drug and anticoagulation therapies. We provide brief updates of recently published articles along with our perspective on how they will likely alter clinical practice now and in the future.
KW - Anticoagulation
KW - Atrial fibrillation
KW - Dabigatran
KW - Dronedarone
KW - Medical therapy
KW - Vernakalant
UR - http://www.scopus.com/inward/record.url?scp=81255185150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81255185150&partnerID=8YFLogxK
U2 - 10.1007/s11886-011-0199-9
DO - 10.1007/s11886-011-0199-9
M3 - Article
C2 - 21744157
AN - SCOPUS:81255185150
SN - 1523-3782
VL - 13
SP - 387
EP - 393
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 5
ER -